Cargando…

Lanzhang Granules Ameliorate Nonalcoholic Fatty Liver Disease by Regulating the PPARα Signaling Pathway

BACKGROUND: There is still a lack of effective therapeutic drugs for nonalcoholic fatty liver disease (NAFLD) to date. In this study, we applied mouse model experiments to clarify the effect of Chinese herbal medicine “Lanzhang Granules (LZG)” on NAFLD and further explore the potential mechanism to...

Descripción completa

Detalles Bibliográficos
Autores principales:	Huang, Ping, Yang, Lili, Liu, Yang, Jiang, Yuwei, Li, Yiping, Chen, Zhiwei, Song, Haiyan, Zheng, Peiyong
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Hindawi 2022
Materias:	Research Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8759917/ https://www.ncbi.nlm.nih.gov/pubmed/35035496 http://dx.doi.org/10.1155/2022/1124901

Ejemplares similares

Hyodeoxycholic acid ameliorates nonalcoholic fatty liver disease by inhibiting RAN-mediated PPARα nucleus-cytoplasm shuttling
por: Zhong, Jing, et al.
Publicado: (2023)

Scoparone Improves Nonalcoholic Steatohepatitis Through Alleviating JNK/Sab Signaling Pathway-Mediated Mitochondrial Dysfunction
por: Jiang, Yuwei, et al.
Publicado: (2022)

Structural and Functional Modulation of Gut Microbiota by Jiangzhi Granules during the Amelioration of Nonalcoholic Fatty Liver Disease
por: Wang, Rui-rui, et al.
Publicado: (2021)

Update on Pparγ and Nonalcoholic Fatty Liver Disease
por: Ables, Gene P.
Publicado: (2012)

Fimasartan Ameliorates Nonalcoholic Fatty Liver Disease through PPARδ Regulation in Hyperlipidemic and Hypertensive Conditions
por: Lee, Yong-Jik, et al.
Publicado: (2017)

Lingguizhugan Decoction Protects against High-Fat-Diet-Induced Nonalcoholic Fatty Liver Disease by Alleviating Oxidative Stress and Activating Cholesterol Secretion
por: Yang, Lili, et al.
Publicado: (2017)

Intervening TNF-α via PPARγ with Gegenqinlian Decoction in Experimental Nonalcoholic Fatty Liver Disease
por: Wang, Yun-liang, et al.
Publicado: (2015)

Novel Selective PPARα Modulator Pemafibrate for Dyslipidemia, Nonalcoholic Fatty Liver Disease (NAFLD), and Atherosclerosis †
por: Yamashita, Shizuya, et al.
Publicado: (2023)

Lentinan Protects against Nonalcoholic Fatty Liver Disease by Reducing Oxidative Stress and Apoptosis via the PPARα Pathway
por: Du, Tingyi, et al.
Publicado: (2022)

Role of Apolipoprotein A1 in PPAR Signaling Pathway for Nonalcoholic Fatty Liver Disease
por: Chen, Changxi, et al.
Publicado: (2022)

Jiang-Zhi granules decrease sensitivity to low-dose CCl(4) induced liver injury in NAFLD rats through reducing endoplasmic reticulum stress
por: Yang, Lili, et al.
Publicado: (2019)

Sijunzi, Lizhong, and Fuzilizhong Decoction Alleviate Nonalcoholic Fatty Liver Disease through Activation of PPAR Pathway
por: Yang, Jiayao, et al.
Publicado: (2020)

Cinnamic Acid Ameliorates Nonalcoholic Fatty Liver Disease by Suppressing Hepatic Lipogenesis and Promoting Fatty Acid Oxidation
por: Wu, You, et al.
Publicado: (2021)

Update on Berberine in Nonalcoholic Fatty Liver Disease
por: Liu, Yang, et al.
Publicado: (2013)

Ablation of the deubiquitinase USP15 ameliorates nonalcoholic fatty liver disease and nonalcoholic steatohepatitis
por: Baek, Jung-Hwan, et al.
Publicado: (2023)

Effect of miR-34a in regulating steatosis by targeting PPARα expression in nonalcoholic fatty liver disease
por: Ding, Jiexia, et al.
Publicado: (2015)

The Therapeutic Effect of Berberine in the Treatment of Nonalcoholic Fatty Liver Disease: A Meta-Analysis
por: Wei, Xiaoyun, et al.
Publicado: (2016)

Hepatocyte-Secreted Autotaxin Exacerbates Nonalcoholic Fatty Liver Disease Through Autocrine Inhibition of the PPARα/FGF21 Axis
por: Qiu, Han, et al.
Publicado: (2022)

LB100 ameliorates nonalcoholic fatty liver disease via the AMPK/Sirt1 pathway
por: Chen, Xue-Yang, et al.
Publicado: (2019)

Aspirin Improves Nonalcoholic Fatty Liver Disease and Atherosclerosis through Regulation of the PPARδ-AMPK-PGC-1α Pathway in Dyslipidemic Conditions
por: Han, Yoon-Mi, et al.
Publicado: (2020)

Palmitate-induced Regulation of PPARγ via PGC1α: a Mechanism for Lipid Accumulation in the Liver in Nonalcoholic Fatty Liver Disease
por: Maruyama, Hitoshi, et al.
Publicado: (2016)

The Effects of PPAR Agonists on Atherosclerosis and Nonalcoholic Fatty Liver Disease in ApoE(−/−)FXR(−/−) Mice
por: Lee, Yenna, et al.
Publicado: (2021)

Combined metabolic activators therapy ameliorates liver fat in nonalcoholic fatty liver disease patients
por: Zeybel, Mujdat, et al.
Publicado: (2021)

Swimming exercise ameliorates insulin resistance and nonalcoholic fatty liver by negatively regulating PPARγ transcriptional network in mice fed high fat diet
por: Zhang, Yong, et al.
Publicado: (2023)

The Efficacy and Safety of Traditional Chinese Medicine (Jiang Zhi Granule) for Nonalcoholic Fatty Liver: A Multicenter, Randomized, Placebo-Controlled Study
por: Pan, Jielu, et al.
Publicado: (2013)

Herbal therapy for ameliorating nonalcoholic fatty liver disease via rebuilding the intestinal microecology
por: Yang, Xiao-Fang, et al.
Publicado: (2021)

Clinical study of ganshuang granule combined with tenofovir in the treatment of chronic hepatitis B complicated with nonalcoholic fatty liver disease
por: Su, Changtian, et al.
Publicado: (2022)

Myeloid-specific blockade of Notch signaling ameliorates nonalcoholic fatty liver disease in mice
por: Ding, Jian, et al.
Publicado: (2023)

Supplementation of Lycium barbarum Polysaccharide Combined with Aerobic Exercise Ameliorates High-Fat-Induced Nonalcoholic Steatohepatitis via AMPK/PPARα/PGC-1α Pathway
por: Li, Dou-Dou, et al.
Publicado: (2022)

The Role of Thiazolidinediones in the Amelioration of Nonalcoholic Fatty Liver Disease: A Systematic Review
por: Ndakotsu, Andrew, et al.
Publicado: (2022)

Misregulation of PPAR Functioning and Its Pathogenic Consequences Associated with Nonalcoholic Fatty Liver Disease in Human Obesity
por: Videla, Luis A., et al.
Publicado: (2012)

The PPAR α/γ Agonist Saroglitazar Improves Insulin Resistance and Steatohepatitis in a Diet Induced Animal Model of Nonalcoholic Fatty Liver Disease
por: Kumar, Divya P., et al.
Publicado: (2020)

Exercise in mice ameliorates high-fat diet-induced nonalcoholic fatty liver disease by lowering HMGCS2
por: Qian, Xiaoli, et al.
Publicado: (2021)

Synergistic effects of black ginseng and aged garlic extracts for the amelioration of nonalcoholic fatty liver disease (NAFLD) in mice
por: Jiang, Guihun, et al.
Publicado: (2021)

Cardiomyocyte-Restricted Deletion of PPARβ/δ in PPARα-Null Mice Causes Impaired Mitochondrial Biogenesis and Defense, but No Further Depression of Myocardial Fatty Acid Oxidation
por: Liu, Jian, et al.
Publicado: (2011)

Establishment and Comparison of Juvenile Female Mouse Models of Nonalcoholic Fatty Liver Disease and Nonalcoholic Steatohepatitis
por: Zhou, Lishan, et al.
Publicado: (2018)

Caffeoylquinic Acid-Rich Extract of Aster glehni F. Schmidt Ameliorates Nonalcoholic Fatty Liver through the Regulation of PPARδ and Adiponectin in ApoE KO Mice
por: Lee, Yong-Jik, et al.
Publicado: (2017)

Melatonin alleviates cadmium-induced nonalcoholic fatty liver disease in ducks by alleviating autophagic flow arrest via PPAR-α and reducing oxidative stress
por: Sun, Jian, et al.
Publicado: (2023)

Current Clinical Trial Status and Future Prospects of PPAR-Targeted Drugs for Treating Nonalcoholic Fatty Liver Disease
por: Kamata, Shotaro, et al.
Publicado: (2023)

Amelioration of Intestinal Barrier Dysfunction by Berberine in the Treatment of Nonalcoholic Fatty Liver Disease in Rats
por: Li, Donghao, et al.
Publicado: (2017)

Cannot write session to /tmp/vufind_sessions/sess_974u1dc8321a2t2rlcv16450k3